论文部分内容阅读
目的 研究肺癌组织中端粒酶活性的表达及其临床意义。方法 采用定量放射端粒重复序列扩增法 (TRAP)检测 74例肺组织中 ( 4 5例为NSCLC ,15例SCLC ,结核 7例 ,炎性假瘤 7例 )端粒酶的活性。结果 NSCLC端粒酶阳性率为 73 .3 % ,且活性较弱 ( 172TPG) ,SCLC端粒酶的阳性率为 93 .3 % ,且活性较强 ( 2 88TPG)。结核与炎性假瘤端粒酶活性全为阴性。SCLC端粒酶活性显著高于NSCLC(P <0 .0 5 ) ,且酶的活性水平与肺癌组织分化程度、肿瘤大小、淋巴结转移及临床分期有密切关系 (P <0 .0 5 )。结论 端粒酶可能是判断肺癌预后不良的指标之一。
Objective To study the expression of telomerase activity in lung cancer and its clinical significance. Methods The telomerase activity in 74 lung tissues (45 NSCLC, 15 SCLC, 7 tuberculosis and 7 inflammatory pseudotumor) was detected by quantitative radioactive telomere repeat amplification assay (TRAP). Results The positive rate of telomerase in NSCLC was 73.3% and its activity was weaker (172TPG). The positive rate of telomerase in SCLC was 93.3% and its activity was strong (888TPG). Tuberculosis and inflammatory pseudotumor telomerase activity were all negative. The telomerase activity of SCLC was significantly higher than that of NSCLC (P <0.05). The activity level of SCLC was closely related to the degree of differentiation, tumor size, lymph node metastasis and clinical stage (P <0.05). Conclusion Telomerase may be one of the indicators to judge the prognosis of lung cancer.